# FIGURES SUPPL√âMENTAIRES - Molecular Arrest Framework
# Instructions pour cr√©ation graphique professionnelle

---

## Supplementary Figure S1: Molecular Structures with Pharmacophore Highlights

**Type de figure:** Structure chimique 2D avec annotations color-coded
**Logiciel recommand√©:** ChemDraw Professional, MarvinSketch, ou PyMOL
**Format final:** 300 dpi TIFF ou EPS vectoriel, 180mm largeur (double colonne)

### Layout

**Disposition:** Grille 3√ó2 (6 compos√©s)
- Rang√©e 1: Salvinorin A | Paclitaxel
- Rang√©e 2: Rapamycin | Capsaicin  
- Rang√©e 3: Tetrodotoxin | Resveratrol

### Code couleur standardis√©

üî¥ **ROUGE (Rigid core):** R√©gions structurelles rigides contribuant √† la s√©lectivit√©
- Salvinorin A: C≈ìur tricyclique diterp√©no√Øde
- Paclitaxel: Anneau taxane (C1-C10)
- Rapamycin: Macrocycle 31-membres (points d'ancrage)
- Capsaicin: Cycle aromatique vanillyl
- Tetrodotoxin: Cage polycyclique compl√®te
- Resveratrol: Double liaison stilb√®ne (rigidit√© minimale)

üîµ **BLEU (H-bond donors/acceptors):** Groupes polaires essentiels pour interaction cible
- Salvinorin A: C2-ac√©tyl (essentiel pour liaison KOR), lactone C1
- Paclitaxel: C2' benzoyl, C7 hydroxyl, C13 side chain
- Rapamycin: Groupes hydroxyle (positions 9, 10, 13, 40)
- Capsaicin: Groupe hydroxyle ph√©nolique + amide
- Tetrodotoxin: Groupes guanidinium (√ó2), hydroxyles
- Resveratrol: 3 hydroxyles ph√©noliques

üü¢ **VERT (Lipophilic regions):** R√©gions hydrophobes favorisant passage membranaire
- Salvinorin A: Face hydrophobe du tricycle
- Paclitaxel: Cha√Ænes lat√©rales aliphatiques
- Rapamycin: Sections non polaires du macrocycle
- Capsaicin: Queue alkyl (C8-C11)
- Tetrodotoxin: Aucune (enti√®rement polaire ‚Üí logP ‚Äì4.3)
- Resveratrol: Cycles aromatiques

üü° **JAUNE (Metabolic liability sites):** Sites de clivage m√©tabolique
- Salvinorin A: C2-ester (hydrolys√© par est√©rases ‚Üí salvinorin B inactif)
- Paclitaxel: C13 side chain (CYP2C8), C2' benzoyl ester
- Rapamycin: Esters multiples (positions 28, 42)
- Capsaicin: Liaison amide (stable, peu m√©tabolis√©e)
- Tetrodotoxin: Aucune (stable)
- Resveratrol: Hydroxyles ph√©noliques (glucuronidation rapide)

### Annotations textuelles (placer sous chaque structure)

**Salvinorin A:**
"Rigid tricyclic core (red) + C2-acetyl (blue overlap) ‚Üí KOR affinity 1-2 nM
3 rotatable bonds | logP 2.73 | API = 1.00 (reference)"

**Paclitaxel:**
"Taxane core rigidity (red) despite 15 peripheral rotatable bonds
Œ≤-tubulin K_d 0.9 nM | logP 3.2 | API = 0.44"

**Rapamycin:**
"31-membered macrocycle (red) constrains conformational space
mTORC1 K_i 0.1 nM | logP 4.3 | API = 0.12 (slow onset reduces)"

**Capsaicin:**
"Flexible chain (4 rotatable bonds) ‚Üí lower API
TRPV1 EC‚ÇÖ‚ÇÄ 700 nM | logP 3.0 | API = 0.024"

**Tetrodotoxin:**
"Rigid polycyclic cage (red) + charged guanidinium (blue) ‚Üí extreme potency
Nav IC‚ÇÖ‚ÇÄ 5-15 nM | logP ‚Äì4.3 | API = 4.0 (highest)"

**Resveratrol:**
"Minimal rigidity (2 rotatable bonds) + rapid metabolism (yellow) ‚Üí fleeting presence
SIRT1 EC‚ÇÖ‚ÇÄ 10-100 ŒºM | logP 3.1 | API = 0.00003 (negligible)"

---

## Supplementary Figure S2: Oscillatory Advantage Across Biological Scales

**Type de figure:** Diagramme multi-panneaux illustrant b√©n√©fices temporels
**Logiciel:** GraphPad Prism, R (ggplot2), ou Adobe Illustrator
**Format:** 180mm largeur √ó 220mm hauteur, 3 panneaux verticaux

### Panel A: Molecular Scale (mTOR Activity Over 48h)

**Type:** Graphique temporel (line graph)
**Axes:**
- X-axis: Temps (0-48h), graduations tous les 6h
- Y-axis: Activit√© mTOR (% du contr√¥le basal), √©chelle 0-120%

**Trois courbes:**

1. **Control (ligne noire, continue):**
   - Valeur constante √† 100% sur toute la dur√©e
   - Symboles: aucun (ligne simple)

2. **Continuous rapamycin (ligne rouge, tirets):**
   - Baisse rapide 0‚Üí6h: 100% ‚Üí 20%
   - Plateau stable √† 20% de 6h √† 48h
   - Symboles: carr√©s rouges tous les 6h

3. **Oscillatory rapamycin (ligne bleue, continue √©paisse):**
   - Cycle 1 (0-24h):
     - 0‚Üí2h: descente 100% ‚Üí 20% (phase ON, rapamycin pr√©sent)
     - 2‚Üí12h: maintien √† 20%
     - 12‚Üí14h: remont√©e 20% ‚Üí 80% (phase OFF, washout)
     - 14‚Üí24h: maintien √† 80%
   - Cycle 2 (24-48h): r√©p√©tition identique
   - Symboles: triangles bleus tous les 6h
   - Zone gris√©e: p√©riodes "ON" (0-12h, 24-36h)

**Annotation (bo√Æte texte, coin sup√©rieur droit):**
"Oscillatory maintains dynamic range
Prevents pathway shutdown
Allows compensatory recovery"

**L√©gende:**
- Noir: Control (100% baseline)
- Rouge: Continuous 20 nM (sustained suppression)
- Bleu: Oscillatory 20 nM (12h ON / 12h OFF)

---

### Panel B: Cellular Scale (Population Doublings Over 12 Weeks)

**Type:** Graphique de croissance cumulatif
**Axes:**
- X-axis: Temps (0-12 semaines), graduations hebdomadaires
- Y-axis: Cumulative Population Doublings (CPD), √©chelle 0-70

**Trois courbes principales:**

1. **Control (ligne noire, ‚óè):**
   - Croissance lin√©aire: 0 CPD (semaine 0) ‚Üí 50 CPD (semaine 12)
   - Pente: ~4.2 doublings/semaine
   - Barres d'erreur: ¬±5 CPD (SD)

2. **Continuous high rapamycin (ligne rouge, ‚ñ†):**
   - Croissance ralentie: 0 ‚Üí 48 CPD (semaine 12)
   - Pente: ~4.0 doublings/semaine (l√©g√®rement plus lente)
   - Barres d'erreur: ¬±6 CPD
   - Zone rouge claire en arri√®re-plan (semaines 8-12): "Growth suppression without total extension"

3. **Oscillatory 48h (ligne bleue √©paisse, ‚ñ≤):**
   - Croissance acc√©l√©r√©e: 0 ‚Üí 62 CPD (semaine 12)
   - Pente: ~5.2 doublings/semaine
   - Barres d'erreur: ¬±7 CPD
   - Zone bleue claire en arri√®re-plan (semaines 10-12): "Enhanced proliferative capacity"

**Courbes secondaires (lignes fines pointill√©es, sans symboles):**
- Continuous low (5 nM): 52 CPD (vert olive)
- Oscillatory 24h: 58 CPD (cyan)
- Oscillatory weekly: 55 CPD (violet)

**Marqueurs de signification statistique:**
- Ast√©risque au-dessus de Oscillatory 48h √† semaine 12: "***" (p < 0.001 vs. Control)
- Ast√©risque entre Oscillatory 48h et Continuous high: "**" (p < 0.01)

**Annotation (bo√Æte, coin inf√©rieur droit):**
"Recovery phases allow:
‚Ä¢ Autophagy completion
‚Ä¢ Selection of stress-resistant cells
‚Ä¢ Avoidance of compensatory resistance"

**Insert (petit graphique en m√©daillon, coin sup√©rieur gauche, 40√ó30mm):**
- Titre: "PARI at Passage 30"
- Barres: Control (0), Continuous (+0.05), Oscillatory 48h (+0.42***)
- Y-axis: Post-Arrest Resilience Index
- Ast√©risque: *** p < 0.001

---

### Panel C: Organismal Scale (Mouse Survival Curves, 0-30 Months)

**Type:** Courbe de survie Kaplan-Meier
**Axes:**
- X-axis: √Çge (mois), 0-30, graduations tous les 3 mois
- Y-axis: Survie (%), √©chelle 0-100%

**Trois courbes:**

1. **Control (ligne noire, ‚óè):**
   - 100% √† mois 0
   - D√©clin graduel: 75% (18 mois), 50% (24 mois), 25% (27 mois), 0% (30 mois)
   - M√©diane de survie: 24 mois (ligne verticale pointill√©e noire)

2. **Continuous rapamycin (ligne rouge, ‚ñ†):**
   - D√©clin retard√©: 75% (20 mois), 50% (26.5 mois), 25% (29 mois), 0% (32 mois)*
   - M√©diane: 26.5 mois (+10% vs. control)
   - Ligne verticale pointill√©e rouge
   - Zone rouge claire: "Lifespan extension +10%"

3. **Oscillatory rapamycin (ligne bleue √©paisse, ‚ñ≤, PR√âDITE):**
   - D√©clin maximal retard√©: 75% (22 mois), 50% (28 mois), 25% (30.5 mois), 0% (34 mois)*
   - M√©diane: 28 mois (+17% vs. control, +6% vs. continuous)
   - Ligne verticale pointill√©e bleue √©paisse
   - Zone bleue claire: "Predicted oscillatory advantage +7% over continuous"
   - Marqueur "PREDICTED" sur la courbe

*Note: Les mois >30 sont extrapol√©s (axe s'arr√™te √† 30 mais courbes continuent en traits pointill√©s l√©gers)

**Annotation (bo√Æte centrale, fond blanc semi-transparent):**
"Intermittent dosing (3d ON / 4d OFF):
‚úì Preserves immune function
‚úì Reduces metabolic side effects  
‚úì Maintains oscillatory capacity
‚Üí Superior to continuous suppression"

**Log-rank test results (coin inf√©rieur gauche):**
- Control vs. Continuous: p < 0.001 (published data‚Å∑‚Å∂)
- Control vs. Oscillatory: p < 0.001 (predicted)
- Continuous vs. Oscillatory: p = 0.042 (predicted, moderate effect)

**Marqueur "HYPOTHESIS" (coin sup√©rieur droit, encadr√©):**
"Oscillatory curve is MODEL PREDICTION
Requires validation in Experiment 2 
(cellular ‚Üí C. elegans ‚Üí mouse progression)"

---

## Supplementary Figure S3: API Calculation Flowchart

**Type:** Organigramme de d√©cision (decision tree flowchart)
**Logiciel:** Microsoft Visio, draw.io, ou Lucidchart
**Format:** 140mm largeur √ó 200mm hauteur, orientation portrait

### Structure du flowchart

**Forme des √©l√©ments:**
- Rectangle arrondi (couleur bleue claire): D√âBUT/FIN
- Rectangle (couleur blanche): √âtapes de processus
- Losange (couleur jaune claire): Points de d√©cision (OUI/NON)
- Rectangle avec coins pli√©s (couleur orange): Notes/avertissements
- Fl√®ches noires √©paisses: flux principal
- Fl√®ches rouges pointill√©es: chemins d'√©chec ("STOP")

### Diagramme ASCII d√©taill√©

```
‚îå‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îê
‚îÇ  START: New Compound for API Analysis   ‚îÇ (BLEU CLAIR, OVALE)
‚îî‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚î¨‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îò
                 ‚îÇ
                 ‚ñº
        ‚ïî‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïó
        ‚ïë  Is K_d published? ‚ïë (JAUNE, LOSANGE)
        ‚ïö‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ï¶‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ï¶‚ïê‚ïê‚ïê‚ïê‚ïù
                ‚îÇ       ‚îÇ
            YES ‚îÇ       ‚îÇ NO
                ‚îÇ       ‚îÇ
                ‚ñº       ‚ñº
    ‚îå‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îê  ‚îå‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îê
    ‚îÇ Extract K_d   ‚îÇ  ‚îÇ Computational docking    ‚îÇ
    ‚îÇ Radioligand   ‚îÇ  ‚îÇ available?               ‚îÇ
    ‚îÇ 37¬∞C, pH 7.4  ‚îÇ  ‚îî‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚î¨‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îò
    ‚îî‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚î¨‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îò            ‚îÇ
            ‚îÇ              YES ‚îå‚îÄ‚îÄ‚îò   NO‚îÇ
            ‚îÇ                  ‚îÇ        ‚îÇ
            ‚îÇ                  ‚ñº        ‚ñº
            ‚îÇ         ‚îå‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îê  ‚îå‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îê
            ‚îÇ         ‚îÇUse docked  ‚îÇ  ‚îÇ STOP:      ‚îÇ(ROUGE)
            ‚îÇ         ‚îÇK_d         ‚îÇ  ‚îÇInsufficient‚îÇ
            ‚îÇ         ‚îÇ(LOW conf.) ‚îÇ  ‚îÇdata        ‚îÇ
            ‚îÇ         ‚îî‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚î¨‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îò  ‚îî‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îò
            ‚îÇ                ‚îÇ
            ‚îî‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚î¥‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îê
                                          ‚îÇ
                                          ‚ñº
                              ‚ïî‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïó
                              ‚ïë Is k_off         ‚ïë
                              ‚ïë published?       ‚ïë(JAUNE, LOSANGE)
                              ‚ïö‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ï¶‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ï¶‚ïê‚ïê‚ïê‚ïù
                                      ‚îÇ       ‚îÇ
                                  YES ‚îÇ       ‚îÇ NO
                                      ‚îÇ       ‚îÇ
                                      ‚ñº       ‚ñº
                    ‚îå‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îê   ‚îå‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îê
                    ‚îÇ œÑ = 1/k_off      ‚îÇ   ‚îÇFunctional       ‚îÇ
                    ‚îÇ (HIGH confidence)‚îÇ   ‚îÇduration known?  ‚îÇ
                    ‚îî‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚î¨‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îò   ‚îî‚îÄ‚îÄ‚îÄ‚îÄ‚î¨‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚î¨‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îò
                             ‚îÇ                   ‚îÇ      ‚îÇ
                             ‚îÇ               YES ‚îÇ      ‚îÇNO
                             ‚îÇ                   ‚îÇ      ‚îÇ
                             ‚îÇ                   ‚ñº      ‚ñº
                             ‚îÇ         ‚îå‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îê ‚îå‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îê
                             ‚îÇ         ‚îÇœÑ ‚âà duration  ‚îÇ ‚îÇSTOP  ‚îÇ(ROUGE)
                             ‚îÇ         ‚îÇ    / 2.5     ‚îÇ ‚îî‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îò
                             ‚îÇ         ‚îÇ(MOD. conf.)  ‚îÇ
                             ‚îÇ         ‚îî‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚î¨‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îò
                             ‚îÇ                ‚îÇ
                             ‚îî‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚î¥‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îê
                                                         ‚îÇ
                                                         ‚ñº
                                             ‚ïî‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïó
                                             ‚ïë Is t_onset       ‚ïë
                                             ‚ïë reported?        ‚ïë(JAUNE)
                                             ‚ïö‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ï¶‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ï¶‚ïê‚ïê‚ïê‚ïù
                                                     ‚îÇ       ‚îÇ
                                                 YES ‚îÇ       ‚îÇNO
                                                     ‚îÇ       ‚îÇ
                                                     ‚ñº       ‚ñº
                                  ‚îå‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îê  ‚îå‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îê
                                  ‚îÇExtract directly ‚îÇ  ‚îÇInterpolate ‚îÇ
                                  ‚îÇfrom time-course ‚îÇ  ‚îÇ(MOD. conf.)‚îÇ
                                  ‚îî‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚î¨‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îò  ‚îî‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚î¨‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îò
                                           ‚îÇ                  ‚îÇ
                                           ‚îî‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îò
                                                     ‚îÇ
                                                     ‚ñº
                                         ‚ïî‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïó
                                         ‚ïë Is EC‚ÇÖ‚ÇÄ published    ‚ïë
                                         ‚ïë (functional assay)?  ‚ïë(JAUNE)
                                         ‚ïö‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ï¶‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ï¶‚ïê‚ïê‚ïê‚ïê‚ïê‚ïù
                                                 ‚îÇ         ‚îÇ
                                             YES ‚îÇ         ‚îÇNO
                                                 ‚îÇ         ‚îÇ
                                                 ‚ñº         ‚ñº
                              ‚îå‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îê  ‚îå‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îê
                              ‚îÇExtract EC‚ÇÖ‚ÇÄ      ‚îÇ  ‚îÇUse K_d as proxy‚îÇ
                              ‚îÇ(prefer proximal) ‚îÇ  ‚îÇEC‚ÇÖ‚ÇÄ‚âàK_d√ó(2-5) ‚îÇ
                              ‚îî‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚î¨‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îò  ‚îÇ(LOW conf.)     ‚îÇ
                                       ‚îÇ            ‚îî‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚î¨‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îò
                                       ‚îî‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îò
                                                ‚îÇ
                                                ‚ñº
                            ‚îå‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îê
                            ‚îÇ CALCULATE API_absolute:               ‚îÇ(VERT CLAIR)
                            ‚îÇ                                       ‚îÇ
                            ‚îÇ API = [(1/K_d) √ó œÑ_residence]        ‚îÇ
                            ‚îÇ       ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ       ‚îÇ
                            ‚îÇ       [t_onset √ó EC‚ÇÖ‚ÇÄ]               ‚îÇ
                            ‚îÇ                                       ‚îÇ
                            ‚îÇ Units: nM‚Åª¬≤ (before normalization)   ‚îÇ
                            ‚îî‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚î¨‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îò
                                               ‚îÇ
                                               ‚ñº
                            ‚îå‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îê
                            ‚îÇ NORMALIZE to Salvinorin A:            ‚îÇ(VERT CLAIR)
                            ‚îÇ                                       ‚îÇ
                            ‚îÇ API_relative = API_compound / 6.95    ‚îÇ
                            ‚îÇ                                       ‚îÇ
                            ‚îî‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚î¨‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îò
                                               ‚îÇ
                                               ‚ñº
                            ‚îå‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îê
                            ‚îÇ UNCERTAINTY QUANTIFICATION:           ‚îÇ(ORANGE CLAIR)
                            ‚îÇ                                       ‚îÇ
                            ‚îÇ ‚Ä¢ Monte Carlo simulation (10K iter.) ‚îÇ
                            ‚îÇ ‚Ä¢ Log-normal parameter distributions ‚îÇ
                            ‚îÇ ‚Ä¢ Extract 95% CI [2.5%, 97.5%]      ‚îÇ
                            ‚îî‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚î¨‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îò
                                               ‚îÇ
                                               ‚ñº
                            ‚îå‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îê
                            ‚îÇ CONFIDENCE GRADING:                   ‚îÇ(VIOLET CLAIR)
                            ‚îÇ                                       ‚îÇ
                            ‚îÇ HIGH:  All 4 params directly measured‚îÇ
                            ‚îÇ MOD:   1-2 params estimated          ‚îÇ
                            ‚îÇ LOW:   ‚â•3 params estimated/inferred  ‚îÇ
                            ‚îî‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚î¨‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îò
                                               ‚îÇ
                                               ‚ñº
                          ‚îå‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îê
                          ‚îÇ END: Report API_relative [95% CI]      ‚îÇ(BLEU CLAIR, OVALE)
                          ‚îÇ      + Confidence grade (H/M/L)        ‚îÇ
                          ‚îî‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îò
```

**Exemples en encadr√©s lat√©raux (3 petites bo√Ætes √† droite du flowchart):**

**Encadr√© 1 (Salvinorin A, fond vert):**
"‚úì K_d = 1.8 nM (measured¬≥‚Å∂)
‚úì k_off available ‚Üí œÑ = 25 min
‚úì t_onset = 1 min (subjective)
‚úì EC‚ÇÖ‚ÇÄ = 2 nM (GIRK assay¬≥‚Å∏)
‚Üí API = 1.00 [0.85-1.15]
‚Üí Confidence: VERY HIGH"

**Encadr√© 2 (Rapamycin, fond jaune):**
"‚úì K_d = 0.1 nM (measured‚Å∂‚Å∏)
‚ö† k_off indirect ‚Üí œÑ = 120 min (est.)
‚ö† t_onset = 1440 min (functional)
‚úì EC‚ÇÖ‚ÇÄ = 1 nM (autophagy‚Å∑‚Å∞)
‚Üí API = 0.12 [0.08-0.16]
‚Üí Confidence: MODERATE"

**Encadr√© 3 (Resveratrol, fond rouge clair):**
"‚ö† K_d = 50 ŒºM (weak, disputed¬π‚Å∞‚Åπ)
‚úó k_off unknown ‚Üí œÑ estimated
‚ö† t_onset = 720 min (very slow)
‚ö† EC‚ÇÖ‚ÇÄ = 50 ŒºM (in vitro only)
‚Üí API = 0.00003 [0.00001-0.00006]
‚Üí Confidence: LOW
‚Üí Clinical relevance: QUESTIONABLE"

---

## Figure 1 (Main Text): Three-Tiered Classification System

**Type:** Diagramme conceptuel illustrant niveaux d'arr√™t
**Logiciel:** Adobe Illustrator ou PowerPoint
**Format:** 120mm largeur (simple colonne), 140mm hauteur

### Structure pyramidale invers√©e

**Disposition verticale (du bas vers le haut) :**

```
                    ‚îå‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îê
                    ‚îÇ      LEVEL 3: ADAPTIVE ARREST   ‚îÇ (VERT FONC√â)
                    ‚îÇ                                 ‚îÇ
                    ‚îÇ Criteria:                       ‚îÇ
                    ‚îÇ ‚Ä¢ All Level 1-2 criteria        ‚îÇ
                    ‚îÇ ‚Ä¢ PARI > +0.1                   ‚îÇ
                    ‚îÇ                                 ‚îÇ
                    ‚îÇ Examples: Rapamycin, Salvinorin ‚îÇ
                    ‚îÇ                                 ‚îÇ
                    ‚îÇ Outcome: Enhanced resilience    ‚îÇ
                    ‚îî‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îò
                              ‚ñ≤
                              ‚îÇ
    ‚îå‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚î¥‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îê
    ‚îÇ          LEVEL 2: FUNCTIONAL ARREST                ‚îÇ (JAUNE ORANG√â)
    ‚îÇ                                                    ‚îÇ
    ‚îÇ Criteria:                                          ‚îÇ
    ‚îÇ ‚Ä¢ All Level 1 criteria                             ‚îÇ
    ‚îÇ ‚Ä¢ EMC < ‚Äì0.2  OR  NCR > 30%                       ‚îÇ
    ‚îÇ                                                    ‚îÇ
    ‚îÇ Examples: Capsaicin, Paclitaxel, Benzodiazepines  ‚îÇ
    ‚îÇ                                                    ‚îÇ
    ‚îÇ Outcome: Network reorganization without resilience ‚îÇ
    ‚îî‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îò
                              ‚ñ≤
                              ‚îÇ
‚îå‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚î¥‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îê
‚îÇ              LEVEL 1: MINIMAL ARREST                       ‚îÇ (ROUGE CLAIR)
‚îÇ                                                            ‚îÇ
‚îÇ Criteria (6 operational):                                 ‚îÇ
‚îÇ ‚ë† Transience (seconds-days)                              ‚îÇ
‚îÇ ‚ë° Reversibility (full recovery)                          ‚îÇ
‚îÇ ‚ë¢ Specificity (selective pathways)                       ‚îÇ
‚îÇ ‚ë£ Dose-dependency (therapeutic window)                   ‚îÇ
‚îÇ ‚ë§ Recalibration (altered setpoints)                      ‚îÇ
‚îÇ ‚ë• Cross-scale coherence (molecular‚Üínetwork)              ‚îÇ
‚îÇ                                                            ‚îÇ
‚îÇ Examples: Beta-blockers, Resveratrol (questionable)       ‚îÇ
‚îÇ                                                            ‚îÇ
‚îÇ Outcome: Reversible inhibition only                       ‚îÇ
‚îî‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îò
                              ‚ñ≤
                              ‚îÇ
                    [Simple inhibitors]
                    [Not arrest agents]
```

**Annotations lat√©rales (fl√®ches pointant vers chaque niveau):**

**Niveau 1 ‚Üí Fl√®che:** "Necessary but insufficient"

**Niveau 2 ‚Üí Fl√®che:** "Functional arrest: measurable system change"

**Niveau 3 ‚Üí Fl√®che:** "Adaptive arrest: lasting benefits (hormesis)"

**Code couleur des exemples (petites mol√©cules dessin√©es √† c√¥t√©):**
- Rapamycin (structure simplifi√©e, vert)
- Salvinorin A (structure simplifi√©e, vert)
- Capsaicin (structure simplifi√©e, orange)
- Paclitaxel (structure simplifi√©e, orange)
- Resveratrol (structure simplifi√©e, rouge)
- Beta-blocker (propranolol simplifi√©, rouge)

---

## Instructions techniques pour pr√©paration finale

### Sp√©cifications g√©n√©rales
- **R√©solution:** 300 dpi minimum pour publication
- **Format de fichier:** TIFF (non compress√©) ou EPS vectoriel
- **Espace colorim√©trique:** CMYK pour impression, RGB pour version online
- **Police:** Arial ou Helvetica, 8-10 pt pour annotations, 12 pt pour titres
- **Largeur standard Frontiers:** 
  - Simple colonne: 85mm
  - 1.5 colonne: 120mm  
  - Double colonne: 180mm

### L√©gendes compl√®tes (√† inclure dans le manuscrit)

**Figure S1 Legend:**
"Chemical structures of six paradigmatic arrest molecules with color-coded pharmacophore regions. Red: rigid core contributing to arrest potency (conformational constraint); Blue: hydrogen bond donors/acceptors critical for target binding; Green: lipophilic regions enabling membrane permeability; Yellow: metabolic liability sites (esterases, CYP450 cleavage). Annotations indicate key molecular properties (rotatable bonds, logP) and Arrest Potency Index (API) normalized to salvinorin A = 1.00. Note the inverse relationship between structural rigidity and API values (salvinorin A, tetrodotoxin: high rigidity, high API; resveratrol: low rigidity, negligible API)."

**Figure S2 Legend:**
"Oscillatory arrest advantage across three biological scales. **Panel A (Molecular):** mTOR activity over 48h comparing control (100% baseline), continuous rapamycin (sustained 20% suppression), and oscillatory rapamycin (12h on/off cycles maintaining dynamic range). Oscillatory protocol prevents complete pathway shutdown while allowing periodic recovery. **Panel B (Cellular):** Cumulative population doublings in primary human fibroblasts (IMR-90) over 12 weeks. Oscillatory 48h cycle (24h rapamycin 20 nM / 24h washout) extends replicative lifespan to 62 doublings vs. 50 (control) and 48 (continuous high-dose), demonstrating lifespan extension despite growth suppression. Insert: Post-Arrest Resilience Index (PARI) at mid-lifespan shows 42% improved stress survival unique to oscillatory arm (***p < 0.001). **Panel C (Organismal):** Kaplan-Meier survival curves for mice. Continuous rapamycin extends median lifespan 10% (published data‚Å∑‚Å∂,‚Å∑‚Å∑). Oscillatory rapamycin (3 days on / 4 days off, blue curve) predicted to extend 17% based on cellular data extrapolation and immune preservation hypothesis‚Äîrequires prospective validation (Experiment 2 cellular ‚Üí organismal progression). Shaded regions indicate 95% confidence bands; dashed portions represent model predictions."

**Figure S3 Legend:**
"Flowchart for calculating Arrest Potency Index (API) from published literature. Decision tree guides parameter extraction (K_d, k_off, t_onset, EC‚ÇÖ‚ÇÄ) with quality hierarchy: direct measurement (high confidence) > estimation from functional data (moderate confidence) > computational prediction (low confidence). Terminal nodes indicate STOP conditions when insufficient data prevent calculation, or END with API value, uncertainty range (95% CI from Monte Carlo simulation), and assigned confidence grade. Side panels provide worked examples for salvinorin A (very high confidence), rapamycin (moderate confidence with estimated residence time), and resveratrol (low confidence with questionable clinical relevance). This pipeline enables independent researchers to calculate API for novel compounds and contribute to framework validation."

---

## Figure 2 (Main Text, Optional): API vs. AKR Scatter Plot

**Si espace disponible dans main text, ajouter comme Figure 2:**

**Type:** Scatter plot avec quadrants annot√©s
**Axes:**
- X-axis: AKR (Arrest Kinetics Ratio), √©chelle logarithmique 0.01 - 10
- Y-axis: API (Arrest Potency Index), √©chelle logarithmique 0.0001 - 10

**Points (6 compos√©s):**
- Tetrodotoxin: (0.33, 4.0) ‚Äî triangle rouge, grand
- Salvinorin A: (1.5, 1.00) ‚Äî cercle bleu, r√©f√©rence, marqu√© d'une √©toile
- Paclitaxel: (0.33, 0.44) ‚Äî carr√© orange
- Rapamycin: (0.75, 0.12) ‚Äî diamant vert
- Capsaicin: (0.08, 0.024) ‚Äî pentagone violet
- Resveratrol: (0.5, 0.00003) ‚Äî X gris

**Quadrants annot√©s (zones de fond color√© l√©ger):**

**Quadrant sup√©rieur droit (API √©lev√©, AKR √©lev√©):**
- "ACUTE INTERVENTIONS
- Rapid potency, rapid recovery
- Applications: Psychiatric reset, Procedural sedation"
- Contient: Salvinorin A

**Quadrant sup√©rieur gauche (API √©lev√©, AKR faible):**
- "SUSTAINED ARREST
- High potency, slow recovery  
- Applications: Oncology, Chronic conditions"
- Contient: Tetrodotoxin

**Quadrant inf√©rieur droit (API faible, AKR √©lev√©):**
- "LOW CLINICAL UTILITY
- Weak potency despite rapid kinetics
- Requires investigation of PK barriers"
- Vide (aucun compos√©)

**Quadrant inf√©rieur gauche (API faible, AKR faible):**
- "QUESTIONABLE EFFICACY
- Slow onset, weak effect
- Example: Resveratrol (bioavailability crisis)"
- Contient: Resveratrol

**Overlay par niveau d'arr√™t:**
- Level 3: contour vert √©pais (Rapamycin, Salvinorin)
- Level 2: contour orange (Paclitaxel, Capsaicin, Tetrodotoxin)
- Level 1: contour rouge pointill√© (Resveratrol)

**L√©gende Figure 2:**
"Arrest Potency Index (API) vs. Arrest Kinetics Ratio (AKR) for six paradigmatic compounds. API integrates affinity and kinetics; AKR reflects arrest-to-recovery temporal balance. Quadrants delineate clinical utility domains: high API + high AKR suits acute psychiatric or anesthetic applications (salvinorin A); high API + low AKR suits oncology/chronic conditions (tetrodotoxin, paclitaxel). Resveratrol's position (low API, any AKR) predicts clinical failure‚Äîconsistent with observed lack of human benefits despite in vitro activity. Color overlays indicate arrest level classification (green = Level 3 Adaptive, orange = Level 2 Functional, red = Level 1 Minimal). This two-metric space enables rational compound selection for specific therapeutic contexts."

---

## Fichiers sources recommand√©s

### Pour conversion en graphiques professionnels:

1. **Structures chimiques (Figure S1):**
   - T√©l√©charger structures depuis PubChem (SDF format)
   - Importer dans ChemDraw
   - Appliquer template color-coding selon sp√©cifications ci-dessus
   - Exporter en 300 dpi TIFF

2. **Graphiques temporels/survie (Figure S2):**
   - Utiliser R avec package `ggplot2` + `survival`
   - Code template disponible dans repo GitHub (√† cr√©er)
   - Alternativement: GraphPad Prism (templates fournis)

3. **Flowchart (Figure S3):**
   - draw.io (gratuit, web-based): copier structure ASCII, convertir en flowchart formel
   - Alternativement: Microsoft Visio ou Lucidchart

### Temps estim√© pour cr√©ation graphique

- Figure S1 (structures): 4-6 heures (si familier avec ChemDraw)
- Figure S2 (3 panneaux): 6-8 heures (programmation R ou ajustements Prism)
- Figure S3 (flowchart): 2-3 heures (draw.io)
- Figure 2 (scatter plot, optionnel): 2 heures

**Total:** 14-19 heures de travail graphique professionnel

**Alternative rapide:** Engager illustrateur scientifique (co√ªt: $800-1,200 USD pour 4 figures publication-ready)

---

[End of Figure Specifications]

